Bristol-Myers Squibb Company

NYSE BMY

Bristol-Myers Squibb Company Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024: -7.59%

Bristol-Myers Squibb Company Return on Assets (ROA) is -7.59% for the Trailing 12 Months (TTM) ending September 30, 2024, a -186.08% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Bristol-Myers Squibb Company Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2023 was 8.82%, a 35.65% change year over year.
Bristol-Myers Squibb Company Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2022 was 6.50%, a 236.07% change year over year.
Bristol-Myers Squibb Company Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2021 was -4.78%, a -13,818.92% change year over year.
Bristol-Myers Squibb Company Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2020 was -0.03%, a -100.21% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NYSE: BMY

Bristol-Myers Squibb Company

CEO	Dr. Christopher S. Boerner Ph.D.
IPO Date	June 1, 1972
Location	United States
Headquarters	430 East 29th Street
Employees	34,100
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Key trends

Past 5 years